Aesyra, an Ecublens (VD) based medtech startup pioneering oral appliance technologies to improve sleep, has raised $3 million in a seed financing round led by Supermoon Capital (USA), the world’s first fund focused on sleeptech, and deep tech investor Creadd Ventures (Switzerland) with participation from existing investor Zürcher Kantonalbank.
The new financing will support the development and commercialization of Aesyra’s AesyBite line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea. “This significant investment marks a pivotal moment for Aesyra,” said Marco Letizia, founder and CEO of Aesyra. “We are thrilled to partner with Supermoon Capital and Creadd Ventures, who share our vision of driving meaningful change within the sleep industry. With their support, we are well-positioned to accelerate the deployment of our groundbreaking solutions, ultimately improving patient outcomes and advancing healthcare practices.”
Since its founding in 2017, Aesyra has been tackling Sleep bruxism, a sleep disorder often linked to sleep apnea, which affects nearly a billion people worldwide. A spinoff from the EPFL, Aesyra has developed a powerful technology system that combines a unique oral appliance device, proprietary sensors, and Artificial Intelligence.
Its flagship product, AesyBite Active, is the first dental product that actively records the occlusal activity exerted during sleep bruxism episodes using the embedded force sensors. The device helps reduce bruxism while monitoring the condition with an easy-to-use mobile app. The technology is based on algorithms that leverage over ten years of sleep research data. It has demonstrated over 70% reduction in bruxism activity for users.
“Aesyra’s advanced technology is a tremendous breakthrough in the field of sleep science for the treatment of sleep bruxism and sleep apnea,” said Michael Masterson, Managing Partner at Supermoon Capital. “We are impressed by the company’s unique approach, strong leadership team and unwavering commitment to revolutionize healthcare, and we look forward to working closely with Aesyra to support its mission.”
“We selected Aesyra as the first investment of Creadd Ventures since it perfectly fits our philosophy to invest in companies that have the potential to make a profound impact on the quality of life of patients,” said Lorenzo Leoni, Founder and Managing Partner at Creadd Ventures. In line with the investment, Masterson and Leoni will join the Board of Directors of Aesyra, bringing their extensive industry expertise and strategic guidance to accelerate the company’s growth and success.
Supermoon Capital is the only venture capital firm in the world focused exclusively on the sleep technology market. The San Francisco-based firm partners with visionary innovators across the sleep market spectrum while Creadd Ventures is a new venture capital fund with a focus on investing Biomedical, DeepTech and SAAS companies based in Switzerland and Europe. The Zurich Cantonal Bank also joined the round.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines